APA (7th ed.) Citation

Woyach, J., Tedeschi, A., Munir, T., Siddiqi, T., Hillmen, P., Byrd, J. C., . . . Barr, P. M. (2021). Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & Lymphoma, 62(13), 3278. https://doi.org/10.1080/10428194.2021.1957871

Chicago Style (17th ed.) Citation

Woyach, Jennifer, et al. "Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma." Leukemia & Lymphoma 62, no. 13 (2021): 3278. https://doi.org/10.1080/10428194.2021.1957871.

MLA (9th ed.) Citation

Woyach, Jennifer, et al. "Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma." Leukemia & Lymphoma, vol. 62, no. 13, 2021, p. 3278, https://doi.org/10.1080/10428194.2021.1957871.